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Abstract
Background: Breast cancer in men is an infrequent occurrence, accounting for ~1% of all breast tumors with an incidence of
about 1:100,000. The relative rarity of male breast cancer (MBC) limits our understanding of the epidemiologic, genetic and
clinical features of this tumor.
Methods: From 1997 to 2003, 10 MBC patients were referred to our Institute for genetic counselling and BRCA1/2 testing.
Here we report on the genetic and phenotypic characterization of 10 families with MBC from the North East of Italy. In
particular, we wished to assess the occurrence of specific cancer types in relatives of MBC probands in families with and without
BRCA2 predisposing mutations. Moreover, families with recurrent BRCA2 mutations were also characterized by haplotype
analysis using 5 BRCA2-linked dinucleotide repeat markers and 8 intragenic BRCA2 polymorphisms.
Results: Two pathogenic mutations in the BRCA2 gene were observed: the 9106C>T (Q2960X) and the IVS16-2A>G (splicing)
mutations, each in 2 cases. A BRCA1 mutation of uncertain significance 4590C>G (P1491A) was also observed. In families with
BRCA2 mutations, female breast cancer was more frequent in the first and second-degree relatives compared to the families
with wild type BRCA1/2 (31.9% vs. 8.0% p = 0.001). Reconstruction of the chromosome phasing in three families and the analysis
of three isolated cases with the IVS16-2A>G BRCA2 mutation identified the same haplotype associated with MBC, supporting
the possibility that this founder mutation previously detected in Slovenian families is also present in the North East of our
Country. Moreover, analysis of one family with the 9106C>T BRCA2 mutation allowed the identification of common haplotypes
for both microsatellite and intragenic polymorphisms segregating with the mutation. Three isolated cases with the same
mutation shared the same intragenic polymorphisms and three 5' microsatellite markers, but showed a different haplotype for
3' markers, which were common to all three cases.
Conclusion: The 9106C>T and the IVS16-2A>G mutations constitute recurrent BRCA2 mutations in MBC cases from the
North-East of Italy and may be associated with a founder effect. Knowledge of these two recurrent BRCA2 mutations
predisposing to MBC may facilitate the analyses aimed at the identification of mutation carriers in our geographic area.
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Background
Approximately 5–10% of breast and ovarian cancer cases
are hereditary, occurring mainly in women with germ-line
mutations in the BRCA1 or BRCA2 genes [1-4]. Although
earlier estimates suggested that BRCA1 and BRCA2 muta-
tions were responsible for 75% of breast cancer families
[4-7] recent population-based studies indicate that these
rates may have been overestimated. In fact, the percentage
of high-risk families associated with BRCA1 and BRCA2
mutations seems to be around 25% in all groups investi-
gated [8-12].
BRCA1 germ-line mutations are also associated with an
increased risk of other cancer types, including those affect-
ing colon, pancreas, stomach and fallopian tubes [13,14].
Other possible sites of cancer for BRCA1 mutation carriers
included cutaneous melanoma, basal cell carcinoma and
sarcoma [15]. Although BRCA1 mutations have been
described also in men with breast cancer, the presence of
germ-line mutations in the BRCA1 gene does not seem to
convey a significantly increased risk for MBC [16]. How-
ever, this issue is still controversial, since a recent study
carried out in 483 BRCA1 mutation carriers reported a 58-
fold increased risk [13].
Available evidence indicates that BRCA2 mutation carriers
have an increased risk of breast cancer in both males and
females, as well as of prostate and pancreatic carcinomas.
Carcinomas of the stomach, gallbladder bile ducts, cuta-
neous melanoma, and basal cell carcinoma are also
slightly more prevalent in carriers of BRCA2 mutations
[17,18]. The large majority of data accumulated so far
indicates that, unlike what reported for female breast can-
cer (FBC), MBC is mainly linked to BRCA2 gene muta-
tions. In fact, up to 30% of MBC were associated with
BRCA2 mutations, whereas only less than 4% of the cases
carried BRCA1 gene mutations, with variable percentages
depending on founder mutations [19,20].
To date, only few studies have attempted to estimate the
risk of breast cancer in male carriers of a BRCA2 mutation.
The analysis of two large families carried out by Easton et
al. [21] resulted in a cumulative risk of MBC of 6.3% (95%
CI 1.4% to 25.6%) by age 70. In contrast, the study by
Thompson et al. [17], based on 59 cases, failed to detect a
significantly higher cumulative risk of MBC by 70 years of
age (2.8%; 95% CI 0.6 – 13.0%). However, the risk
increased to 6.9% (95% CI 1.2% to 38,6%) by 80 years,
80-fold higher compared to the general population. The
present study was carried out with the aim to characterize
the genetic and phenotypic features of families with MBC
from the North East of Italy. In particular, we wished to
assess the occurrence of specific cancer subtypes in first,
second and third degree relatives of MBC probands in
families with and without BRCA2 predisposing muta-
tions. Moreover, we also searched for the presence of
recurrent mutations in this area due to a possible founder
effect.
Methods
From 1997 to 2003, 197 patients with breast or ovarian
cancer with a family history of these tumors were referred
for genetic counselling to the Centro di Riferimento
Oncologico (National Cancer Institute, Aviano, Italy).
The present study is part of an Institutional program on
hereditary tumors approved by local Ethical Committee.
Families were selected according to previously reported
criteria [22]. All consecutive male patients with a breast
cancer, independently of age and family history, were
included and counselled for genetic testing for BRCA1 and
BRCA2 gene mutations. Ten families were ascertained by
a male index case; one patient with MBC (BR175) also
developed prostatic cancer at the age of 66 (Table 1). One
additional male patient (BR331), showing an atypic intra-
cystic papilloma of the breast together with a melanoma
of the ear, was not included in the statistical analysis. All
individuals tested for BRCA1/2 mutations gave a signed
informed consent.
Blood samples were obtained from each proband and
after the identification of a specific mutation the analyses
were extended to 98 relatives. Screening for mutations in
the BRCA1 and BRCA2 genes was carried out by a combi-
nation of protein truncation test, single strand conforma-
tion polymorphism, and sequencing techniques (Table
1). Primer sequences and PCR conditions were previously
described [22,23]. All mutations and genetic variants were
named according to Antonarakis et al. [24]. Missense
mutations and mutations occurring within intronic
regions whose clinical significance has not yet been
reported were defined as genetic unclassified variants.
Germline rearrangements of BRCA1 and BRCA2 gene
were also analysed by multiplex ligation dependent probe
amplification (MLPA).
The haplotype associated with the 9106C>T BRCA2 muta-
tion was analyzed using five BRCA2-linked di-nucleotide
repeat markers: D13S290, D13S260, D13S1698,
D13S171, and D13S1695, whereas for the IVS16-2A>G
mutation the D13S290, D13S171, and D13S1695 mark-
ers were used.
The first three markers were placed in 3' flanking of the
BRCA2 gene whereas the other two were placed in the 5'
flanking of the BRCA2 gene. The order of markers from
centromere to telomere is as follows: cen-D13S290,
D13S260, D13S1698, D13S171, D13S1695-tel. PCR
products were analyzed on the ABI Prism 3100 using the
POP4 matrix and fluorescently labelled primers. For these
markers, a heterozygosity of 46%, 78%, 63%, 72%, andBMC Cancer 2006, 6:156 http://www.biomedcentral.com/1471-2407/6/156
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79% has been reported in the Genome Data Base, respec-
tively [25]. Alleles were numbered according to the size of
each microsatellite repeat marker. The disease-associated
haplotypes were deduced from allelic segregation in
known carriers by inspection of segregating genotypes in
the analyzed families. Moreover, for the haplotype analy-
sis of the 9106C>T mutation, eight internal BRCA2 poly-
morphisms were analyzed: 203G>A (exon 2),
IVS8+56C>T (intron 8), 1342A>C (exon 10), 3624A>G
(exon 11), 4035T>C (exon 11), IVS11+80del4 (intron
11), 7470A>G (exon 14), IVS16-14T>C (intron 16). For
the haplotype analysis only, besides the 4 families ascer-
tained by a MBC index case, 6 additional families were
also analyzed, two carrying of the 9106C>T mutation and
4 with the IVS16-2A>G mutation. All these families were
ascertained by a FBC index case, showed a positive family
history of breast and/or ovarian cancer and came from the
same geographic area.
Statistical analyses
The first and second degree relatives of the male index case
of BRCA2 positive families were compared to first and sec-
ond degree relatives of families without a BRCA2 muta-
tion but with or without familial history for breast cancer,
using chi-square analyses [26]. The family with a BRCA1
mutation with unclear significance was excluded from this
comparison. Odds Ratios (OR), and their corresponding
95% Confidence Interval (CI), was computed using
unconditional logistic regression model [27] in order to
calculate the odds to develop a tumor in the first and sec-
ond degree relatives conditional on the BRCA2 status of
the proband.
Table 1: Clinicopathologic and genetic characteristics of the 10 MBC cases analyzed for the presence of BRCA1/2 mutations.
Family Patient Age TNM histology ER PR Method Mutation Effect Affected relatives
25 BR 22 40 N.A. N.A. N.A. N.A. PTT-SSCP 9106C>T Q2960X BC(31)s, BC(48)s, 
BC(44)s, BC(30)s, 
BC(65)s, BC(37)ptc.
103 BR 111 59 pT1N0 intraductal carcinoma N.A. N.A. PTT-SSCP MLPA w.t. BC(78)s, BC(75)pta, 
BC(55)ptc, 
BC(N.A.)ptc, 
BC(60)ptc, 
BC(60)ptc, 
BC(58)ptc, 
BC(60)ptc.
125 BR 138 62 pTis intraductal carcinoma + + PTT-SSCP MLPA w.t. BC(82)m.
127 BR 140 52 pT1cN0 infiltrating ductal 
carcinoma
+ + PTT-SSCP MLPA w.t. BC(55)mta, 
BC(47)mta, 
PC(61)mtu, 
BC(45)mtc, 
BCbil.(35)mtc, 
BC(42)mtc.
139 BR 173 58 pT2N1b
iii
infiltrating ductal 
carcinoma
+ + PTT-SSCP MLPA w.t. /
140 BR 175 58/
66P
C
PT4bN0 infiltrating ductal 
carcinoma
+ + PTT-SSCP 9106C>T Q2960X BCbil.(30)s, 
BC(40)pta, 
BC(48)pta.
161 BR 195 50 N.A. N.A. N.A. N.A. PTT-SSCP IVS16-
2A>G
exon 
skipping
BC(38)f, BC(57)pta, 
PC(N.A.)ptu, 
BC(50)ptgm, 
BC(N.A.)ptggf, 
BC(N.A.)ptga, 
BC(N.A.)ptga.
190 BR 243 70 pT1c infiltrating ductal 
carcinoma
+ + PTT-SSCP IVS16-
2A>G
exon 
skipping
BC(36)d, 
BC(46)OC(N.A.)m, 
BC(N.A.)(OC)(N.A.)
mta, BC(N.A.)mtc.
192 BR 247 38 pT4bN1
biiiM0
infiltrating ductal 
carcinoma
+ + PTT-SSCP MLPA w.t. PC(75)f.
217 BR 282 46 pT1aiii
N0
infiltrating ductal 
carcinoma
+ + PTT-Direct 
Sequencing 
MLPA
4590C>G P1491A BC(N.A.)pta, BC 
(N.A.)ma.
Number between parentheses indicate the age at diagnosis; N.A.: not available; w.t.: wild-type; PTT: protein truncation test; SSCP: single strand 
conformation polymorphism; MLPA: multiplex ligation-dependent probe amplification; mt: maternal; pt: paternal; m: mother; f: father; s: sister; d: 
daughter; gm: grandmother; ggf: great-grandfather; ga: great-aunt; c: cousin; u: uncle; a: aunt. BC: breast cancer; BCbil: bilateral breast cancer; OC: 
ovarian cancer; PC: prostate cancer.BMC Cancer 2006, 6:156 http://www.biomedcentral.com/1471-2407/6/156
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Results
The 10 MBC probands had a mean age at the time of diag-
nosis of 53.3 years (range 38–70 years). 3/10 patients
were younger than 50 years, whereas 7 were ≥50 years.
Only one patient (BR247) developed a breast cancer
before the age of 40. Four of the 10 patients (40%) carried
a predisposing mutation in the BRCA2 gene (Table 1).
Five of the remaining six cases carried wild-type (w.t.)
BRCA1 and BRCA2 genes whereas in one case (BR282) a
missense BRCA1 mutation 4590C>G (P1491A), causing a
Pro>Ala replacement in position 1491 with unclear signif-
icance was observed (Table 1). The family history of this
latter case showed two second-degree female relatives
affected by breast cancer, one belonging to the maternal
side and the other to the paternal side. This mutation was
not reported in the Breast Cancer Information Core data-
base [28]. Although mutations in the BRCA1 gene do not
seem to be associated with increased risk of MBC, further
studies are required to assess the possible predisposing
role of this mutation in case BR282. It was not possible to
assess whether this variant was present in other affected
relatives because none of them was alive.
The six cases negative for point mutations were also ana-
lyzed for BRCA1 and BRCA2 genes rearrangements by
MLPA. None of these cases showed structural alterations
of BRCA1 and BRCA2 genes. The median age of diagnosis
was 54.5 years for the 4 BRCA2 mutation carriers and 53.8
years for the other cases, excluding the unclassified vari-
ant. The 4 BRCA2 positive cases carried only two distinct
mutations: the 9106C>T, involving exon 22 and leading
to a premature protein truncation (cases BR22 and
BR175), and the IVS16-2A>G, involving intron 16 and
leading to a partial or total skipping of exon 17 (cases
BR195 and BR243) [29]. Both these mutations were local-
ized outside the Ovarian Cluster Cancer Region and were
previously reported also by others in the BIC database
(three times for the 9106C>T mutation and four times for
the IVS16-2A>G mutation in all). The carriers of the
IVS16-2A>G mutation and those with the 9106C>T muta-
tion showed a median age of breast cancer onset of 60 and
49 years, respectively.
In one IVS16-2A>G positive family, a first-degree relative
(the father of the BR195 proband) was affected by a MBC
diagnosed at 38 years. When this case was also included in
the analysis, the median age of MBC onset in carriers of
the IVS16-2A>G mutation decreased to 52.7 years.
In 8/10 cases the histologic characterization of the tumor
was available. Invasive ductal carcinoma (75%) was the
most frequent histologic subtype followed by intraductal
carcinoma (25%). Another case, diagnosed as atypic intra-
cystic papilloma, which showed also a melanoma of the
ear, was found negative for BRCA1 and BRCA2 mutations.
This case was not included in the statistical analysis. All
the 6 assessable cases were oestrogen and progesterone
receptors positive by immunohistochemistry (Table 1),
confirming previous findings indicating that MBC have a
higher rate of positivity to hormone receptors than do
FBC (90% vs. 77%) [30]. However, when MBC were com-
pared with cancers from postmenopausal women, the
positivity rates were similar. All our BRCA2 positive cases
showed a positive family history for breast and/or ovarian
cancer (Table 1).
Two out of three cases of prostatic cancers were observed
at 61 and 75 years, respectively, in w.t. families. In the four
BRCA2 mutation carrier families, breast cancer was more
frequent in the first and second-degree relatives than in
the five w.t. families. In fact, as compared with w.t. fami-
lies, in BRCA2 mutation carrier families there was a signif-
icant higher rate of affected first and second degree
relatives (31.9% vs. 8.0% p = 0.001). These results indicate
that first and second degree relatives of index cases with
BRCA2 mutation carrier families have a five times greater
risk to develop a breast cancer (Table 2). The two MBC
cases without family history of cancer resulted negative for
BRCA1/2 mutations. In three of the four families with a
BRCA2 gene mutation, the molecular analysis was
extended to ten non-affected relatives, (six males and four
females), allowing the identification of 5 additional
BRCA2 mutation carriers (2 males and 3 females).
Table 2: Distribution of FBC in relatives of MBC cases belonging to w.t. and BRCA2 mutation carrier families.
w.t. families (n = 5) BRCA2 mutation carrier families (n = 4)
I+II degree relatives I+II degree relatives
N (%) N (%) OR 95% CI
Non-affected 58 (92) 32 (68.1) 1
Affected 5 (8) 15 (31.9) 5.43 (1.81–16.34)
Total 63 47
X1
2 = 10.40; p = 0.001; w.t.: wild-type.BMC Cancer 2006, 6:156 http://www.biomedcentral.com/1471-2407/6/156
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Besides the four MBC cases carrying BRCA2 mutations,
genotype analysis was also carried out in six additional
unrelated cases enrolled for the presence of FBC in the
index case: two with the 9106C>T BRCA2 mutation and
four with the IVS16-2A>G BRCA2 mutation. On the
whole, genotype analysis was performed in four cases
with the 9106C>T BRCA2 mutation, (one family and
three isolated cases), and in six IVS16-2A>G BRCA2 muta-
tion cases (three families and three isolated cases). Recon-
struction of the chromosome phasing was possible in four
families. The analysis carried out in family 25, carrying the
9106C>T BRCA2 mutation, allowed the identification of
a common haplotype (5-6-2-6-6) shared by all mutation
carriers belonging to this family (Figure 1). This haplotype
encompassed a distance of about 3.8 cM between the
D13S290 to D13S1695 markers, and was not detected in
non-carrier relatives. The isolated cases showed the same
allelic pattern for the D13S290, D13S171, and D13S1695
markers, whereas the D13S260 and D13S1698 markers,
located within the 3' region flanking the BRCA2 gene,
showed an allelic pattern (1,1) different from that of
mutation carriers belonging to family 25 (Table 3). There-
fore, all isolated cases had the same 5,1,1,6,6 genotype,
which is in part consistent with the disease causing haplo-
type detected in family 25. However, the analysis of 8
internal BRCA2 polymorphisms showed that the same A-
C-A-G-T-(-4)-G-C haplotype was present in all the
9106C>T mutation carriers investigated (Table 4). The
analysis of 55 healthy donors for 4 of these intragenic pol-
ymorphisms (203G>A, IVS8+56C>T, 7470A>G, IVS16-
14T>C) showed that, without phase reconstructing, only
15 of them (27%) carried the same haplotype detected in
BRCA2 mutation carriers. On these grounds, it is highly
unlikely that these four polymorphisms are simultane-
ously present in the four index cases by chance alone
(p = 0.0085, two-tailed Fisher's exact test).
The haplotype analysis by the reconstruction of the chro-
mosome phasing of three IVS16-2A>G BRCA2 mutation
families, showed that all mutation carriers had the same
5-4-2 haplotype for the D13S290, D13S171, and
D13S1695 markers, whereas all the non-carrier relatives
displayed a different allelic pattern for the three markers
investigated (Table 5).
Pedigree of the family 25 with the reconstruction of the chromosome phasing Figure 1
Pedigree of the family 25 with the reconstruction of the chromosome phasing. The type of cancer and age at diagnosis are indi-
cated. Affected individuals are indicated by a red symbol and proband is denoted by arrow. The shared haplotype segregating 
with 9106C>T mutation is boxed.BMC Cancer 2006, 6:156 http://www.biomedcentral.com/1471-2407/6/156
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Discussion
MBC accounts for less than 1% of all breast cancers and
little is known on the epidemiologic, genetic and clinico-
pathologic features of this malignancy [31-34]. Available
data indicate that the prevalence of BRCA2 mutations in
MBC ranges between 4% and 40% [32-34]. These differ-
ences are probably related to the genetic features of the
families, with higher rates of BRCA2 mutations in men
with a strong family history of cancer, particularly of those
belonging to the BRCA2 spectrum.
In our series, the high prevalence of BRCA2 mutation
(about 40%) correlated with the high number of relatives
with breast cancer present in these families. In fact,
excluding from the analysis the two apparently sporadic
MBC, the frequency of BRCA2 mutations rises up to 50%.
The mean age of breast cancer onset in males with and
without BRCA2 mutations is still a controversial issue
[16,32,35]. In the present study, we found a median age
of diagnosis of 54.5 years for the BRCA2 mutation carriers
(range 40–70 years) and of 53.8 years (range 38–62 years)
for the w.t. type cases, supporting the findings reported by
others [32] indicating that BRCA2 mutation carriers and
noncarriers have a similar age at the time of diagnosis.
It has been reported that about 15–20% of MBC patients
had a first-degree relative with breast carcinoma, support-
ing the notion that a positive family history of breast can-
cer is associated with increased risk of MBC [36,37]. In our
survey, all MBC patients carrying deleterious BRCA2
mutations had a family history of breast cancer. This was
not due to a selection bias, since the eligibility criteria
Table 4: Haplotype analysis of intragenic BRCA2 polymorphisms associated with the 9106C>T BRCA2 mutation.
Polymorphisms Family 25 Isolated cases
Position Nucleotide change BR22 BR23 BR99 BR100 BR101 BR102 BR103 BR175 BR342 TBL 38
M w.t. w.t.M M M w.t.M M M
EX2 203G>A G>A G-G G>A A-A A-A A-A G-G G>A G>A G>A
INTR8 IVS8+56C>T C-C C-C C>T C>T C-C C-C C-C C>T C-C C>T
EX10B 1342A>C A>C C-C A-A A-A A-A A-A C-C A-A A-A A-A
EX11-J 3624A>G A>G A-A A>G G-G G-G G-G A-A A>G A>G A>G
EX11K 4035T>C T-T T-T T>C T-T T-T T-T T-T T-T T>C T-T
INTR11Q IVS11+80del4 -4/4 4/4 -4/4 -4/-4 -4/4 -4/-4 4/4 -4/4 -4/4 -4/4
EX14A 7470A>G A>G A-A A>G G-G G-G G-G A-A A>G A>G A>G
INTR17 IVS16-14T>C T>C T>C T>C C-C C-C C-C T>C C-C T>C T>C
M: mutated; w.t.: wild-type; numbers in bold indicate the shared allele.
Table 3: Genotype analysis of flanking microsatellites associated with the 9106C>T BRCA2 mutation.
Markers carrier (+)/
non carrier (-)
Probands D13S290 D13S260 D13S1698 D13S171 D13S1695
Family 25
BR22 5-5 6-5 2-2 6-6 6-5 +
BR23 5-5 5-3 2-5 6-1 5-8 -
BR99 5-3 2-2 4–6 2-2 5–7 -
BR100 5-4 6-2 2-4 6-2 6-5 +
BR101 5-5 6-1 2-5 6-2 6-2 +
BR102 5-4 6-2 2-4 6-2 6-5 +
B R 1 0 3 5 - 55 - 32 – 56 - 15 – 8 -
Isolated cases
BR175 5,4 1,4 1,1 6,2 6,5 +
BR342 5,3 1,3 1,3 6,2 6,6 +
TBL38 5,5 1,5 1,5 6,2 6,6 +
Numbers in boldface type indicate the 9106C>T mutation alleles. Haplotype segregating with the 9106C>T mutation alleles of phased alleles are 
separated by a dash. Genotypes of unphased alleles are separated by a comma.BMC Cancer 2006, 6:156 http://www.biomedcentral.com/1471-2407/6/156
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used for MBC did not require the presence of a positive
family history. These findings are in keeping with those
reported by others indicating that a positive history of
breast cancer is more frequent in BRCA2 gene mutation
carriers, with values ranging from 13 to 80% [36-38],
although opposite results have been also reported [32]. In
our 8 families with a positive history of breast cancer, the
presence of a deleterious BRCA2 mutation was not associ-
ated with a different occurrence of specific types of cancers
as compared to BRCA2-negative families. A significantly
higher frequency of breast cancers was observed in the
first- and second-degree relatives of mutation carriers,
whereas the prevalence of breast cancers in third degree
relatives was higher in w.t. families.
Similarly to what reported in other studies [33], also the
majority (75%) of our MBC were infiltrating ductal or
intraductal carcinomas. One case was classified as intra-
cystic atypic papilloma a relatively infrequent subtype
accounting for about 2–5% of all MBC [33]. The patient
carrying this tumor was negative to the molecular screen-
ing, as those reported in other series [16], ruling out the
possibility that BRCA1/2 mutations may confer a signifi-
cantly increased risk of developing this peculiar MBC his-
totype.
Available data on the prevalence of BRCA1 and BRCA2
mutations in Italian MBC patients are limited. In a previ-
ous study [16], Ottini et al. reported one BRCA1 and three
BRCA2 mutations including two mutations recurring in
central Italy (BRCA1 3345delAG and BRCA2 6696delTC).
The three BRCA2 mutations identified in this study were
however different from those we observed. Notably, the
MBC cases from our series were characterized by the recur-
rence of a restricted set of BRCA2 mutations detected in
families coming from a limited geographic area (North
East of Italy), suggesting the possible existence of a
founder effect. Indeed, it has been previously reported
that all carriers of the IVS16-2A>G mutation shared a
common haplotype, indicating a likely founder effect
mainly confined to the Slovenian population [39]. Con-
sistently, our haplotype analysis carried out in six Italian
families with the IVS16-2A>G BRCA2 mutation allowed
the detection of a common haplotype shared by all muta-
tion carriers. These findings, taken together, support the
possible occurrence of a founder effect involving the 5'
region flanking the BRCA2 gene in both North-East of
Italy and the neighbouring Slovenia, suggesting that the
IVS16-2A>G BRCA2 mutations probably recognize a com-
mon ancestral origin. The IVS16-2A>G mutation was pre-
viously reported by Krajc et al. [39] in three breast cancer-
only Slovenian families, whereas it was not identified in
three families with ovarian cancer, suggesting that the can-
cer phenotype associated with this mutation is limited to
breast cancer. Conversely, our pedigree's analysis of six
Italian families with the IVS16-2A>G mutation disclosed
the presence of one family in which two ovarian carcino-
Table 5: Genotype analysis of flanking microsatellites associated with the IVS16-2A>G BRCA2 mutation.
Markers Carrier (+)/Non 
carrier (-)
Probands D13S290 D13S171 D13S1695
Family 14
BR6 5-5 4-2 2-5 +
BR73 5-1 2-2 5–6 -
BR82 5-1 4-2 2-6 +
Family 161
BR195 5-5 4-2 2-4 +
BR285 5-5 4-2 2-4 +
BR289 5-2 2-1 4–6 -
Family 190
BR243 5-3 4-4 2-4 +
BR290 5-5 4-5 2-6 +
BR291 3–5 4–5 4–5 -
Isolated cases
BR60 5,5 4,4 2,1 +
BR85 5,5 4,2 2,5 +
BR312 5,5 4,2 2,3 +
Numbers in boldface type indicate the IVS16-2A>G mutation alleles. Haplotype segregating with the IVS16-2A>G mutation alleles of phased alleles 
are separated by a dash. Genotypes of unphased alleles are separated by a comma.BMC Cancer 2006, 6:156 http://www.biomedcentral.com/1471-2407/6/156
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mas were present along with breast cancer, indicating thus
that the risk conferred by this mutation is not restricted to
breast cancer. Moreover, in the six families with the IVS16-
2A>G mutation of our database, two additional MBC
were detected (relatives of patients BR195 and BR312),
further supporting the increased risk of developing breast
cancer in males conferred by this mutation. Since the
IVS16-2A>G mutation can result in either a partial or total
skipping of exon 17 [29], the increased risk for breast can-
cer in males due to this mutation may be related to these
effects on BRCA2 gene transcription. Studies are under
way in our laboratory to elucidate this issue.
With regard to the 9106C>T mutation, the data obtained
by haplotype evaluation coupled with the reconstruction
of chromosome phasing suggest but do not conclusively
prove the occurrence of a possible founder effect also for
this mutation. In fact, all the mutation carriers of Family
25 showed the same haplotype for the markers D13S290-
D13S260-D13S1698-D13S171-D13S1695; however, the
three isolated cases showed a different allelic pattern for
the markers D13S260 and D13S1698 located within the
3' region flanking the BRCA2 gene. These results may
underlie the occurrence of a possible recombination event
involving these two markers in the 3' region flanking the
BRCA2 gene as also suggested by the finding that all muta-
tion carriers of Family 25 and the three isolated cases
shared the same allelic pattern 6-6 for the 5' markers
D13S171 and D13S1695.
In support of this possibility, the analysis of 8 different
intragenic BRCA2 gene polymorphisms demonstrated
that all carriers of the 9106C>T mutation shared the same
haplotype. It can be hypothesized that the common hap-
lotype shared by all mutation carriers could be comprised
within a region starting from the 3' end of the gene and
extending to the 5' flanking microsatellite markers.
The analysis of larger series of families is however required
to conclusively assess whether the 9106C>T mutation is
associated with a founder effect in the North East of Italy,
enlarging thus the number of founder mutations
described for the BRCA2 gene [17,40]. If this will be the
case, it would be of interest to verify whether, similarly to
what observed for the IVS16-2A>G BRCA2 mutation, also
the 9106C>T mutation is associated with a founder effect
shared by people from North-East Italy and Slovenia.
Conclusion
Although carried out on a limited series, the present study
confirms that BRCA2 mutations are associated with a sig-
nificant fraction of breast cancer cases in men. Moreover,
the identification of two recurrent BRCA2 mutations pre-
disposing to MBC may be of practical relevance to opti-
mize the molecular analyses aimed at detecting mutation
carriers in North East of Italy. In fact, the IVS16-2A>G and
the 9106C>T mutations were detected in about 4% of the
families we have investigated so far, whereas the recurrent
and putative founder mutations account for about 12% of
the total. This would support the practical value of starting
the mutational analysis of BRCA2 in the North-East Ital-
ian population with the search for these particular muta-
tions. This may enhance the collection of larger numbers
of families with the same predisposing BRCA2 mutations,
providing thus the basis for studies aimed at identifying
genetic modifying factors that may modulate the pheno-
typic manifestations of MBC.
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